Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05649059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Study acronym: CAN-SAD
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later May 2026 → May 2027
See other at-risk trials from Massachusetts Institute of Technology

Record History

  1. Primary completion pushed from May 2026 to May 2027 Completion pushed from Sep 2026 to May 2027v9 Show 1 more changeShow less
    • Completion pushed from Sep 2026 to May 2027
  2. Re-verified, no change to tracked fieldsv8
  3. Start date changed from estimate of Jun 2025 to Jul 10, 2025v7
  4. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 2025 to Jun 2025 · Study sites: 2 to 1 · Eligibility criteria shortened, about 7 wordsv6 Show 3 more changesShow less
    • Start date: Apr 2025 to Jun 2025
    • Study sites: 2 to 1
    • Eligibility criteria shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: May 2025 to May 2026 Start date: Sep 2024 to Apr 2025 · Completion date: Sep 2025 to Sep 2026v5 Show 2 more changesShow less
    • Start date: Sep 2024 to Apr 2025
    • Completion date: Sep 2025 to Sep 2026
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Dec 2023 to Sep 2024 Primary completion date: Dec 2024 to May 2025 · Completion date: May 2025 to Sep 2025v4 Show 2 more changesShow less
    • Primary completion date: Dec 2024 to May 2025
    • Completion date: May 2025 to Sep 2025
  2. Start date: Apr 2023 to Dec 2023 Primary completion date: Sep 2024 to Dec 2024v3 Show 1 more changeShow less
    • Primary completion date: Sep 2024 to Dec 2024
  3. Start date: Jan 2023 to Apr 2023 Site contacts updated at 1 of 2 sitesv2 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Trial Details
NCT Number NCT05649059
Lead Sponsor Massachusetts Institute of Technology
Collaborators: Massachusetts General Hospital
Conditions Phobia, Social
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov